Tien Dong MD

Nguyen Tien Dong, M.D Nuclear Medicine and Oncology Center, Bach Mai Hospital Address: 78 Giai Phong - Hanoi - Vietnam

[Leila Tchelebi @LeilaTchelebi]

Officially in print! Our ASTRO Clinical Practice Guideline for #GastricCancer #PracticalRO @AnkerUVMRadOnc @ASTRO_org @SalmaJabbour1 https://t.co/UZjACuQDY4

[Tim Brown, MD MSCE @TimothyJBrownMD]

Excited to present our poster evaluating the efficacy and safety of the addition of SBRT to atezolizumab and bevacizumab in advanced HCC at #GI24. Thanks to @Salthecancerguy for the 📸

[Krishan Jethwa @KrishanJethwa]

🚨🚨Ph2R Trial of M0 HCC with PVTT (n=90)

Comparing:

TACE + TKI + SBRT

vs.

TACE + TKI

✅⬆️ mOS with addition of SBRT☢️ (17.9m vs. 9.6m)
✅⬆️6m PFS with SBRT (78% vs. 36%)

🔥🔥🔥 The data supporting SBRT for localized HCC w/ PVTT continues to pile up!!!
#ASCO24

[Gustavo @gusviani]

https://t.co/n99jzY1TbH

[Shankar Siva @_ShankarSiva]

@PBlanchardMD at #SABR2025 - as usual a nuanced, balanced discussion of the role and risks of the role of SABR in head & neck cancers - upfront, in oligomets and re-#radiotherapy #radonc

[Drew Moghanaki @DrewMoghanaki]

Dad joke during his introduction: “We have learned the Green Journal will no longer have Peer Review and instead now have Pierre Review”. 😂 #SABR2025

[Pierre Blanchard, MD @PBlanchardMD]

Practical step by step guidance on how to perform pancreatic #SBRT by @lauren_henke at #SABR2025

#SBRT is the best way to deliver BED>100Gy to this tumors, which likely drives superior survival in #PancreaticCancer

[Shankar Siva @_ShankarSiva]

📣@DrewMoghanaki - “this talk is going to make some of you uncomfortable”… 🥹 good on you Drew for pushing the boundaries in #lungcancer #radonc - Final talk of #SABR2025 🙏🏽

[Gerry Hanna @gerryhanna]

Really great to see Thoracic Sub-Study of our SARON study presented at #ESTRO25

Simultaneous delivery of CFRT to primary (+/- nodes) &
SABR to thoracic mets in synchronous OM-NSCLC
➡️Acceptable acute RT-related adverse
events
➡️No grade >3 adverse events observed

[Jun Gong @jgong15]

Dr. Hoeppner ESOPEC PhIII trial (cT1cN+ or cT2-4acN0/+) esoph adenoCA rand 1:1 periop #FLOT vs neoadj #CROSS ➡️ FLOT superior w/median OS 66 mos vs 37 mos, PFS, & higher pCR (16.8 vs 10%) over CROSS. 52.5% finished adj FLOT, 67.7% finished neoadj CROSS

#ASCO24 @OncoAlert

[Dr. Nina Niu Sanford @NiuSanford]

Good q. If decision is for pre-op therapy for T2N0, I’d favor CROSS due to lower treatment burden, cost, & toxicity for most (obviously exact tradeoffs depend on specific scenario).

Per ESOPEC forest plot, FLOT ~ CROSS for T2 or N0. Can then add on adjuvant nivo per CM577.

[Drew Moghanaki @DrewMoghanaki]

A new publication from @BrendanHeiden et al demonstrates an OS benefit for patients with stage I NSCLC undergoing surgery at VA medical centers with on-site SBRT. The results show that SBRT is being appropriately leveraged to optimize patient selection when available. These data provide further evidence that MDT matters. @ZaidAbdelsattar @kelleymic https://t.co/w0NUG3QILz

[Tien Dong MD @md_tien]

@lymberis I am a doctor from Vietnam. Information on induction treatment for cervical cancer is truly important for us. Could you please share the discussion with me?

[Evan Thomas MD/PhD @EvanThomas84]

A well known thoracic rad onc refused to accept 60Gy/30fx concurrent chemoRT for LS-SCLC as an acceptable treatment regimen on the boards, despite it being the most commonly prescribed fractionation in the US (maybe world?)

I will shoot him dirty looks at ASTRO until he apologizes.

https://t.co/vR0pxai1L6

https://t.co/eLnqdYSw6l

[Drew Moghanaki @DrewMoghanaki]

And then there were EIGHT treatment schedules for LS-SCLC studied in randomized clinical trials. #radonc #WCLC25

1) 45/30 (1.5 Gy QD)
2) 60/40 (1.5 Gy BID)
3) 54/30 (1.8 Gy BID)
4) 60/30 (2 Gy QD)
5) 66/33 (2 Gy QD)
6) 70/35 (2 Gy QD)
7) 42/15 (2.8 Gy QD)
8) 45/15 (3 Gy QD)

[Oncology Brothers @OncBrothers]

#WCLC25 Highlights #CommunityOncology:

1. #FLAUR2 1L EGFR mNSCLC @dplanchard

2. #ACROSS2 1L EGFR mNSCLC @JordiRemon

3. #HARMONi 2L EGFR NSCLC

4. #ALCHEMIST Adj ALK+ NSCLC

5. #NadimAdjuvant Adj ChemoIO NSCLC

#lcsm #OncTwitter @IASLC @DrJNaidoo @NReguart @IsaOpitz

1/6

[Katsuaki Maehara 🇯🇵 @KatsuakiMaehara]

🫁 International Association for the Study of Lung Cancer Staging Project 🫁

@JTOonline
#WCLC25
#LCSM

https://t.co/1ngvQ2wwQI

[Daniel Koffler, MD @dmkoffler]

@toddscarbrough @cpeedell @JoeChangMD How common is 60/30? In my training and at Mayo now we always give at least 66 if we’re doing daily fractions? I agree with both of you — not sure 3 extra fractions makes a difference and adopting daily fractionation in any case is massaging data for convenience…

[Yakup Ergün @dr_yakupergun]

#WCLC25
Great summary by @Larvol 👇

[LARVOL @Larvol]

@IASLC - WCLC 2025 Recap

🔗 Explore more insights and data from #WCLC25: https://t.co/AXs0r27IZ7

#LARVOL #CancerResearch #Oncology #ClinicalTrials #LungCancer #WCLC2025 #IASLC #LCSM #NSCLC #SCLC | @HHorinouchi | @diegoadiazg | @StephenVLiu | @lungoncdoc | @Tony_Calles | @ADesaiMD | @M_Torasawa | @SuyogCancer